Loading clinical trials...

Contrasting the Brain Effects of Risperidone and Invega With Functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET) Scanning | Clinical Trials | Clareo Health

UNKNOWNPHASE4

Contrasting the Brain Effects of Risperidone and Invega With Functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET) Scanning

Contrasting the Brain Effects of Risperidone and Invega With fMRI and PET Scanning

NCT00937261•University of California, Irvine

View on ClinicalTrials.gov

Summary

The purpose of this study is to better understand brain function and psychiatric and neurological illness when taking Invega or Risperdal. The objective is to compare the brain effects of Invega to Risperdal in patients with Schizophrenia. This comparison will be evaluated with PET imaging, fMRI, and neurological ratings and assessments.

Eligibility

Age

18 - 60 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•are currently taking Risperdal and have been on the medication for at least three weeks
•are diagnosed with schizophrenia
•are able to provide written informed consent
•can safely have an MRI

Exclusion Criteria

•are treatment resistant or intolerant to Risperdal
•have participated in another drug study in the past 28 days
•are pregnant or trying to become pregnant or are breastfeeding
•are colorblind
•have a history of alcohol, cannabis, or cocaine abuse within two weeks prior to the study
•have a current or past history of a major medical illness or have abnormal lab values which the study doctor feels is significant
•certain medications are also exclusionary including aripiprazole.

Locations (1)

UC Irvine

Irvine, California, United States

Key Dates

Start Date

July 1, 2009

Primary Completion Date

July 1, 2010

Completion Date

January 1, 2011

Last Updated

October 28, 2010

Enrollment

ESTIMATED participants

Conditions

Schizophrenia

Interventions

Risperidone

DRUG

Paliperidone

DRUG

Contacts

Liv McMillan, B.S.

CONTACT

949-824-3770 liv@uci.edu

Steven G Potkin, M.D.

CONTACT

714-456-5697 sgpotkin@uci.edu

Feasibility, Acceptability, and Preliminary Efficacy of Yoga-based Group Intervention for Outpatients With Schizophrenia Spectrum Disorders

NCT07455929

Psychotic DisordersSchizophrenia Spectrum Disorders

View study

RECRUITING

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

NCT06740383

Schizophrenia Spectrum and Other Psychotic DisordersSchizophrenia+5 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 28, 2010Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Contrasting the Brain Effects of Risperidone and Invega With Functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET) Scanning

Inclusion Criteria

Exclusion Criteria

Feasibility, Acceptability, and Preliminary Efficacy of Yoga-based Group Intervention for Outpatients With Schizophrenia Spectrum Disorders

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia

Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Disorders

Brain Stimulation to the Hippocampus in Schizophrenia

Develop a Novel Occupational Training Program for Schizophrenia Patients Based on Virtual Reality Techniques